Layoffs
There is something of a recurring theme among the life science, healthcare and biopharma industries: shortage of skilled employees will lead to a decrease in innovation.
Since GSK initiated this new focus, the company has made several key moves to support the plan, including the December 2018 acquisition of Tesaro Oncology.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of its sales team, according to reports.
The Pennsylvania-based company disagrees with the FDA’s analysis of its clinical data and will seek to work with the agency for approval.
The latest job cuts at Merrimack come about five months after the company culled 60 percent of its staff.
More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.
The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.
Scott Gottlieb, the proactive commissioner of the U.S. Food and Drug Administration has resigned, according to reports. Gottlieb will leave the regulatory agency in about a month.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know if you’ve updated your resume and components that make it competitive.
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
PRESS RELEASES
